Abstract
The Fontan operation is performed for various cardiac lesions with single-ventricle physiology. The survival rate of Fontan patients is increasing for adolescents and young adults, with an expected 30-year survival of >80%. Medical health care providers including specialists in organ systems and pediatric radiologists need to improve their knowledge about the Fontan circulation and the various organ complications to monitor care. In this review the author explains the basic anatomical and functional features of Fontan palliation and gives an overview of the multiple long-term organ complications that might present in the pediatric population. These include decreased physical capacity, ventricular dysfunction, atrioventricular valve regurgitation and arrhythmia, as well as protein-losing enteropathy, plastic bronchitis, growth/bone composition disturbances, renal dysfunction, and the recently recognized and important liver fibrosis (Fontan-associated liver disease). Neuropsychological and behavioral deficits occur frequently. This review focuses on the key role of radiology in making the diagnosis of these complications, monitoring therapy and predicting outcomes in the pediatric age group. The author discusses how and when radiology is important in Fontan patients, as well as how new techniques enabling quantitative measures in imaging with US, MRI and CT are adapted for pediatric use, and how they contribute to urgently needed surveillance strategies.
Electronic supplementary material
The online version of this article (10.1007/s00247-020-04682-5) contains supplementary material, which is available to authorized users.
Keywords: Child, Computed tomography, Elastography, Fontan circulation, Heart disease, Magnetic resonance imaging, Surveillance, Ultrasonography
Introduction
Four decades after the first operation performed by Francis Fontan, much is still unknown of the pathophysiological mechanisms and complications of Fontan palliation as a lifesaving treatment for single-ventricle congenital heart disease. The ventricular function alone is not predictive for a Fontan patient’s quality of life and the multiple types of problems can interact to give the unique features of complications in this equally exclusive and growing population. These children require lifelong follow-up with medical care, implicating an important financial and societal impact.
The Fontan operation creates an artificial circulation with two serial capillary beds by connecting the superior and inferior caval veins to the pulmonary arteries (Fig. 1) [1]. In the final Fontan circulation, transpulmonary blood flow is driven by a moderately elevated central venous pressure high enough to overcome the pulmonary vascular resistance (Fig. 2) [2]. The most important elements of Fontan circulation include:
reduced cardiac output,
increased central venous pressure and
non-pulsatile hepatic congestion and fibrosis/cirrhosis.
These features have an impact on both visceral organs and lymphatic drainage, causing important complications (Fig. 3) [2–5]. One of the most important effects that is lately gaining more awareness is Fontan-associated liver disease with development of fibrosis/cirrhosis and risk for malignant transformation. Liver disease is of major concern in young adult Fontan patients, whereas the prevalence and impact in the pediatric population is less well explored [6–8].
The cardiac complications with decreased cardiac output go along with decreased physical capacity, ventricular dysfunction, atrioventricular valve regurgitation and arrhythmia. The veno-lymphatic congestion with protein-losing enteropathy and plastic bronchitis are a considerable problem for some patients, as well as renal dysfunction, growth disturbances and bone composition abnormalities that can progress over time. Neurodevelopmental disorders and psychological problems are highly prevalent.
Imaging is gaining an important role in the follow-up of this patient group and, most important, in the evaluation of cardiac, lymphatic and liver function. Cardiac and thoracic CT and cardiac MRI are used to supplement or replace echocardiography and cardiac catheterization for assessing the cardiac status. In addition, with the increasing awareness of other end-organ injuries, new techniques in US, CT and MRI such as elastography, relaxometry with quantitative measures, and lymphatic imaging with image-guided interventions have become increasingly important.
The question is whether and how these children should be followed appropriately to identify treatable complications. One study suggests that with a growing adult population with congenital heart disease, adult congenital cardiologists should assure the transition from pediatric to adult care actively and start this process during early adolescence, continuing until successful engagement [9].
The involvement of multiple organs in Fontan circulation is challenging to manage and requires a multidisciplinary approach by those with medical knowledge of the pathophysiological origin to achieve optimal care for this distinct condition. This includes clinicians from many pediatric and adult specialties, including hepatology, pneumology, endocrinology, cardiology and radiology.
Incidence, prognosis and outcome
Up to 70,000 people with Fontan-type palliation might be alive worldwide, and the population is expected to double the next 20 years [5, 10, 11]. The long-term survival is increasing because of surgical refinements and improved pre-, peri- and postoperative care, but this varies among countries. Today, 20-year survival estimates are 61–85% [2, 11–14]. Known factors negatively influencing outcomes are multiple, such as having a single right ventricle, male gender, common atrioventricular valve, older age at Fontan operation, postoperative complications with increased pulmonary pressures, and prolonged pleural effusions after Fontan completion [3]. Likewise, protein-losing enteropathy, arrhythmia and thromboembolic events are associated with shorter survival.
The Fontan circulation is a palliation, and cardiac transplantation — the only curable treatment for a failing Fontan circulation — has important implications for survival. The paediatric heart network reported 15-year survival results ranging from 0% to 21% across centers among those who received a cardiac transplant after Fontan surgery completion [15].
Pathophysiology
The most common type of heart defect treated with a Fontan operation is hypoplastic left heart syndrome. However, in several other defects with a single functional ventricle such as tricuspid atresia, double-outlet right ventricle, some types of pulmonary atresia, and atrioventricular septum defects, the only treatment option might be the Fontan palliation. In many cases, either the left or the right ventricle is dominant, serving as the systemic ventricle (Fig. 4).
The goal with a Fontan palliation is to create a serial circulation where the systemic venous return via the superior and inferior caval veins reach the pulmonary vascular bed without the pumping pressure of the right ventricle. Instead, systemic venous blood return is driven by increased central venous pressure and without pulsations (Fig. 1).
This passive blood flow does, however, limit the ventricular volume load and thereby limit the possibility of increasing cardiac output during physical activity (Fig. 2). The non-pulsatile flow additionally causes injury of pulmonary vessel walls with elevated pulmonary vascular resistance. Combined with limited capacity of ventricular filling, this leads to a circulatory failure, but not necessarily combined with a failing ventricular pump function [4]. As a compensation, venovenous, aortopulmonary and even pulmonary arteriovenous collaterals develop at the cost of desaturation and cardiac volume overload.
Surgical treatment
The surgical repair is generally performed in planned stages (Fig. 5). The first operation is carried out when necessary shortly after birth to assure sufficient arterial flow and oxygenation to the lungs and body. This operation might differ depending on the type of defect, but in hypoplastic left heart syndrome, a Blalock–Taussig shunt or a central aorto-pulmonary shunt is placed and one common atrium created by a large interatrial defect to secure free return of pulmonary and systemic venous flow (Fig. 5). The following stage of transitional superior cavo-pulmonary connection (either a bidirectional Glenn or cavo-pulmonary connection) is performed at about 6 to 8 months of age. The operation for the final stage, a total cavo-pulmonary connection, is accomplished in most centers when the child weighs about 15 kg, at 2–4 years of age (Fig. 5) [16].
Historically, three main surgical techniques for the final Fontan stage have been used and continuously refined over the years. The initial type was introduced by Francis Fontan in 1971 and was further refined by Guillermo Kreutzer in 1973 using the “atriopulmonary connection,” where the right atrial appendage connects to the left pulmonary artery [1, 17]. In the second, “the lateral tunnel approach,” a tunnel inside the atrium creates a connection to the pulmonary artery to achieve a total cavo-pulmonary connection.
Most children today undergo a third technique, using an extracardiac conduit in Gore-Tex placed lateral to the right of the common atrium between the inferior caval vein and the left pulmonary artery (Fig. 5 and supplementary material) [18]. Some centers perform a fenestration between the conduit and the common atrium to temporarily reduce the central venous pressure, i.e. a controlled right-to-left shunt, at the cost of increased cyanosis. This seems to decrease the amount of immediate postoperative pleural effusion, and the fenestration might eventually close naturally or be closed later [19].
Complications of Fontan circulation and the role of imaging
The Fontan circulation is a life-saving procedure providing many children an acceptable quality of life for several years [20]. However, long-term complications occur, and with increasing severity from adolescence (Table 1; Fig. 3) [5, 6, 21–25]. In single-ventricle physiology, the hemodynamic situation is abnormal already in fetal life, with deprived oxygenation that is detrimental to body organs and further develops after Fontan completion (Table 1; Fig. 3) [24]. Ultimately, this can lead to a “failing Fontan circulation,” a term traditionally used when several and severe complications are present and can lead to death [26]. It does not necessarily include a circulatory failure caused by ventricular dysfunction, but it can be the result of pulmonary vascular dysfunction, thromboembolism, organ failure or arrhythmia. Most imaging techniques using echocardiography, radiography, US, CT, MRI and conventional angiography are applicable for investigating the complications in the heart and in secondary findings in the thorax and end organs.
Table 1.
Organ system | Complication | Radiologic investigation, monitoring |
---|---|---|
General | Reduced physical capacity (present in 100% of patients) | |
Cardiac | Ventricular dysfunction | Echocardiography/cardiac MRI/CT |
Atrioventricular valve regurgitation Arrhythmia | ||
Heart failure | ||
Cyanosis | ||
Lungs | Increased pulmonary vascular resistance |
CT/catheterization Angiography/cardiac MRI |
Aortopulmonary/venovenous collaterals | ||
Liver | Fibrosis/cirrhosis/hepatocellular carcinoma | US, CT, MRI |
Kidney | Renal dysfunction | Doppler US |
Veno-lymphatic system | Lymphangiectasia | MR, lymphangiography |
Plastic bronchitis | MR/CT/lymphangiography | |
Protein-losing enteropathy | Catheterization intervention | |
Bone | Growth disturbances | Radiographic bone age estimation |
Bone mineral deficiency | Bone mineral density measurement | |
Brain | Neurodevelopmental disorders | MR brain |
Cognitive disorders | ||
Behavioral deficits |
CT computed tomography, MRI magnetic resonance imaging, US ultrasonography
Cardiovascular complications
Heart failure and ventricular dysfunction
There are two types of heart failure in Fontan patients. They present as the classic ventricular pump failure and the Fontan circulatory failure. The latter relates to the chronic increased central venous pressure and low cardiac output but with a remaining acceptable ventricular function. The systolic and diastolic ventricular function are relatively preserved the first decades after Fontan completion but decline over time [15]. Systolic dysfunction is present in 40–60% of patients considered for heart transplantation [27]. The function might be improved if treatment is possible for coexisting complications such as atrioventricular valve regurgitation, arrhythmia, venovenous and arteriovenous collaterals, and vascular obstructions like stenosis (Fig. 6). Reliable quantification of the function is difficult in single-ventricle physiology because of the complex diverse anatomy and lack of normal reference values and functional indexes for a non-left ventricular systemic ventricle [28].
Atrioventricular valve regurgitation
Historically, significant atrioventricular valve regurgitation was a contraindication for the final Fontan operation, but today medication and options to replace or repair the valve are possible. However, it is still an important complication with often insidious development that can lead to volume overload, ventricular dilation and dysfunction. This can compromise the Fontan circulation, especially in a tricuspid valve serving as a systemic valve [29]. Preoperative evaluation and quantification of ventricular function and valve regurgitation are important to decide the optimal surgical approach and time point [30, 31].
Arrhythmias
Both the anatomy of the single-ventricle congenital heart defect and the type of surgery performed pose a risk for arrhythmia, which occurs in about 41% of Fontan patients [32]. Arrhythmias are associated with increased mortality, morbidity and atrial/ventricular arrhythmia focus (90/10%) [32]. Sinus node dysfunction is predominant in children with extracardiac conduit. Treatment options include antiarrhythmic medication and catheter-based ablation, different modes of pacing or, in specific cases, an implantable cardioverter defibrillator.
Thromboembolic events
Fontan patients have increased risk of developing thrombosis and bleeding. The chronic low oxygen saturation in Fontan patients, about 90–95% at rest, leads to increased hemoglobin and blood viscosity. Together with venous stasis, a low cardiac output and indwelling central lines lead to a hypercoagulable state. On the other hand, intrinsic alterations in thrombophilia factors increase the risk for bleeding. There is no consensus on the use of thromboprophylaxis, which leaves up to one-third of patients at risk of a thromboembolic event. Pulmonary embolism is one of the major mortalities in Fontan patients (Fig. 7) [33].
Imaging in cardiovascular complications
Two-dimensional (2-D) echocardiography is the easiest and first choice of investigation for functional and anatomical examination, with new techniques enabling volumetric measurements, 3-D and 4-D imaging, myocardial strain analysis, and feature tracking [34]. However, interpretation is partly subjective and often hampered, especially for the right ventricle, by limited cardiac views related to patient habitus and postoperative conditions.
Cardiac MRI is the standard for reliable serial evaluation of ventricular performance, valve function and flow data, with the added possibility of an anatomical overview with multiplanar and volume-rendered reconstructions (Fig. 6). Contrast media based on gadolinium or ferumoxytol can enhance the morphology, enabling 3-D print models of the heart defect [35, 36]. Functional flow data can be provided by 2-D phase-contrast sequences, while newer quantitative MR techniques like 4-D flow with computational fluid dynamics are under research and in clinical use in a few institutions and require specific software analysis tools (Fig. 8) [37–39]. MR strain analysis and feature tracking are, like echocardiography, newer techniques that are garnering more attention to how diastolic and systolic function perform in the single-ventricle circulation and also in pediatric patients [28, 34].
Magnetic resonance imaging offers the possibility for tissue characterization by relaxometry with T1, T2 and T2* mapping of the myocardium for evaluating evidence of myocardial edema, scarring, diffuse fibrosis and iron deposition [40, 41]. In addition, visualization of the lymphatic system in the thorax with MR lymphography can be employed with and without intravenous contrast agent (Fig. 9) [42]. Many of the new quantitative techniques in MR have only been used in smaller studies in pediatrics and are still under research to provide evidence-based data to prove their usefulness.
Cardiac CT angiography is especially important for coronary artery visualization and in children with MR-incompatible devices or who are not clinically able to undergo a cardiac MRI (Fig. 6). Especially in pediatrics, scanning protocols with radiation-reducing techniques must be used. For Fontan circulation, specific contrast-injection protocols are necessary depending on the clinical question. Knowledge of pitfalls in the interpretation is important [33, 43] (Fig. 7). Functional cardiac information can also be provided by electrocardiography-gated scanning of the whole cardiac cycle at the cost of increased radiation and performed in select cases, such as children with an implantable device like a cardioverter defibrillator [33, 44]. Both MR and CT are used to guide intervention for catheter-based ablation of arrhythmia [45, 46].
Cardiac catheterization provides, invasively, a direct hemodynamic evaluation and the possibility for interventional procedures to relieve and optimize central venous pressure in pulmonary artery stenosis and to treat venovenous or arteriovenous collaterals (Fig. 6). Evaluation before the final Fontan stage of anatomical and functional features is often performed using echocardiography and catheterization in combination. However, many centers prefer cardiac MRI because it is noninvasive, without ionizing radiation, and it provides additional important morphological information and more reliable volumetric measurements than echocardiography [47–49].
Fontan-associated liver disease
Fontan-associated liver disease is an inevitable development after Fontan palliation and is a growing concern for these young patients. Although liver injury caused by cardiac dysfunction has long been recognized [50], in Fontan patients, the chronic elevated central venous pressure without pulsations, lymphatic overflow and hypoxia-induced sinusoidal stress results in fibrosis/cirrhosis with special features where the pathophysiological mechanisms are still not fully understood. Fibrosis can be seen in the first 5 years after Fontan completion [6, 51] and develops in different phases during adolescence/adulthood to end-stage chronic liver disease, where most complications occur, such as portal hypertension with variceal bleeding, ascites, hepatic encephalopathy and hepatocellular carcinoma [6, 8, 23]. Typically, hepatic serological markers are normal or only slightly deranged, with increase in transaminases, glutamyl transferase and bilirubin and with no or few clinical findings until the more advanced stages or development of hepatocellular carcinoma, where serum alpha-fetoprotein might be increased [52]. The venous hypertension mimics a hepatic venous outlet obstruction and gives rise to arterialization of hepatic blood flow with presence of hypervascular nodules [53]. Other types of nodules develop with or without signs of cirrhosis, with hepatocellular carcinoma reported in 1.3% of Fontan patients as young as 12 years [23, 54].
The American College of Cardiology statement on Fontan-associated liver disease and several other reports and researchers advocate for periodic radiologic liver assessment screening and longitudinal follow-up of fibrosis. In addition, there is a need for a workup and a surveillance plan for malignant transformation in the presence of larger nodules [6, 52, 55]. Monitoring liver disease development is important for medical and interventional treatment to optimize the Fontan circulation and to identify the optimal time point for cardiac transplantation [56].
Ultrasonography has been proposed as a first choice of investigation, although it is relatively insensitive in detecting fibrotic changes and can miss nodules, which are often isoechoic with the liver parenchyma [57]. US imaging can, however, identify early phases of congestive hepatopathy and provide hemodynamic information on hepatic flow, important for serial evaluation of fibrosis/cirrhosis development. US elastography, especially shear-wave techniques, is gaining more experience in the serial follow-up in these patients [57, 58]. Increased liver stiffness is present in the immediate Fontan postoperative period and persists in the majority of patients (Fig. 10) [59]. Nonetheless, elastography results must be interpreted with caution in the Fontan population because, unlike in other forms of chronic liver disease, no validated cut-offs of severe liver fibrosis are available, especially in pediatrics [55, 60].
Use of contrast-enhanced US imaging in the liver in Fontan patients has not been reported. Although the second-generation US contrast agents like SonoVue (Bracco, Milan, Italy) are approved for pediatric use to diagnose liver lesions in the United States, off-label use in Europe needs careful consideration. Low frequency of adverse effects is reported but the fact that many Fontan patients have serious cardiac dysfunction and venovenous shunting via collaterals could be a contraindication for use [61, 62].
Computed tomography and MRI provide more detailed and accurate complementary information on structure and morphology of the liver tissue and characterization of the liver nodules in different vascular phases, and for MRI, hepatocyte-specific contrast agents can also be used (Figs. 6, 10 and 11). The liver congestion makes the interpretation of nodular vascular enhancement difficult. For diagnosis of hepatocellular carcinoma, the imaging criteria proposed in the Liver Imaging Reporting and Data System (LIRADS) are less reliable [55, 63]. Therefore, contrary to recommendations in adults with nodules suspicious for malignancy, biopsy is suggested in Fontan patients to verify the diagnosis [7, 55]. The role of liver biopsy as routine in the staging of fibrosis/cirrhosis is under debate. Although considered the gold standard in diagnosing cirrhosis, it is an expensive, invasive procedure with risks of complications and sampling errors because of the heterogeneous distribution in this type of liver disease [7, 52, 64, 65].
Other techniques including diffusion-weighted imaging, MR elastography, and relaxometry with T1, T2 and T1rho mapping have been reported to be useful in the diagnosis and in assessing the central venous pressure (Fig.10) [66–68]. US/MRI shear-wave elastography cannot distinguish hepatic congestion from fibrosis but the composite of these two measures might be of important clinical value in the longitudinal follow-up of Fontan-associated liver disease [55, 58].
The cardiac Fontan surgery leads to acute kidney injury. In addition, the kidneys are susceptible to decreased cardiac output as well as possible nephrotoxic medication, cardiopulmonary bypass runs (inflammation), intravenous iodinated contrast agents and longstanding cyanosis. This Fontan-related renal dysfunction often goes undetected until adolescence and adulthood. Measured renal function, i.e. glomerular filtration as opposed to estimated glomerular filtration, is abnormal in at least 10% of these children, with increasing prevalence in adolescents and adults [5].
Monitoring renal function using US Doppler resistive index is of growing interest as a marker of heart failure and end organ damage in adult congenital heart disease. A recent pediatric Fontan study revealed that a high index >0.81 reflects the severity of heart failure, hepatic and renal function, glucose intolerance and overall mortality [69].
Veno-lymphatic complications
Both protein-losing enteropathy and plastic bronchitis represent the clinical manifestation of chronic venous congestion induced by lymphatic insufficiency and abnormal lymphatic channels [70]. Protein-losing enteropathy affects 3–18% of Fontan patients and is a life-threatening disease when proteins leak into the small bowel [22, 60]. The pathophysiological mechanisms of protein-losing enteropathy in Fontan circulation are incompletely understood and seem to differ compared to other forms. In a recent study by Rodriguez et al. [60], protein-losing enteropathy seemed to be associated with advanced liver disease and markers of inflammation and intestinal permeability. Protein-losing enteropathy diagnosis is made by the evidence of elevated fecal α1-antitrypsin in combination with serum hypoalbuminemia and clinical edemas.
Plastic bronchitis is reported to occur in <5% of individuals with Fontan circulation and consists of thick tenacious casts of lymphatic protein-rich fluid from broncho-lymphatic communications, produced within the bronchial tree. Plastic bronchitis is diagnosed after detection of these casts by patient expectoration or by bronchoscopic removal. The casts can partially or completely obstruct the airway, leading to severe hypoxemia and asphyxiation.
The relationship between lymphatic congestion and end organ damage such as liver fibrosis, protein-losing enteropathy and Vitamin D insufficiency and nutrition needs to be further explored. Both plastic bronchitis and protein-losing enteropathy are challenging to treat medically and until recently there was only one option, cardiac transplantation. Nevertheless, recent advances with surgical and interventional procedures have been quite successful, although with a risk of recurrence because these interventions do not treat the Fontan circulation itself and the inherent venous hypertension [71].
Imaging has quite recently gained an important role to investigate and tailor interventional treatment. Using MR lymphography based on heavily T2-weighted sequences, patterns of lymphatic vascular architecture in the chest and abdomen can be delineated (Fig. 9). When performed in conjunction to the Fontan completion, these patterns have been shown to predict the outcome with high association to protein-losing enteropathy and plastic bronchitis [72]. New treatment options, including surgical and catheter-based intervention to occlude or stent vasculo-lymphatic or bronco-lymphatic pathways, have been successful in small series with good outcomes as well as low morbidity and mortality [42, 73]. Lymphatic conventional angiography and intervention might also be an option in tertiary and specific centers, even with intrahepatic MR lymphography reported [71].
Bone health and growth
Fontan patients have impaired growth with lower stature compared to the normal population.
Decreased Vitamin D levels and increased parathyroid hormone, low lean muscle mass and decreased cortical bone mineral density are key findings in this patient group [5]. In a recent study, bone mineral density levels decreased with age in people with Fontan circulation where different bone components were involved. Vitamin D levels also decreased with age, but this was not consistently associated with bone mineral density [74]. The reason for the decrease of Vitamin D in Fontan patients is unknown but is thought to be related to altered gut circulation and Vitamin D absorption.
Radiographic bone age estimation, especially using automated techniques in addition to bone mineral density measurements like dual-energy X-ray absorptiometry, can be performed to guide treatment. Dual-energy X-ray absorptiometry is of limited value in pediatrics because of the lack of pediatric normal reference values of bone mineral density in the younger age group [75].
Central nervous system and neurocognitive function
There is increasing awareness of neurologic, neurodevelopmental and behavioral abnormalities in congenital heart disease, and especially in Fontan patients. The potential causes of brain injury in congenital heart disease are cumulative and interactive. There are genetic causes, with in utero disturbed hemodynamics that can reduce oxygen delivery and cerebral maturation. Other factors are patient-related, like low birth weight and preterm birth. The different steps of surgical treatment and cardiac catheterization contribute to the risk of hypoxic–ischemic injury and embolic events [25]. Neurocognitive impairment impedes academic achievement and evaluation in early school years. There is a need to target patients who might benefit from interventions. Improving the understanding of how to manage cognitive and psychiatric outcomes in adult congenital heart disease, especially Fontan patients, is a prioritized area of research.
Fetal and neonatal MR studies in children with a single ventricle have shown abnormalities in maturation, volumetric growth and white matter already in fetal life [76–79]. MR findings in later life show striking deviations from normal in most people, with focal and multifocal abnormalities of different degrees. Findings show that non-acute ischemic changes such as atrophy and ventriculomegaly accumulate with staged surgical reconstruction [80]. Typically, spreading white matter abnormalities have been associated with cognitive impairment as well as gray matter abnormalities [81, 82].
Heart transplantation
The only curable treatment for children with Fontan circulation is a heart transplantation. There is an ongoing debate on the optimal time point to perform a transplantation. Many children reach such a serious reduced clinical state before considering transplantation that the procedure itself becomes too dangerous regarding pre-, peri- and postoperative complications [83]. Ventricular assist devices might be necessary to bridge a cardiac transplantation in trying to achieve a better clinical and functional state [84]. Advanced liver cirrhosis and even malignant transformation might prohibit transplantation or require a combined liver and heart transplantation [6]. There has been a high early post-transplantation mortality rate in this patient group, but with better perioperative treatment, survival is increasing and is now comparable to the rate in other types of congenital heart disease undergoing transplantation [85].
Pre- and post-transplantation imaging consists of chest radiography, CT and cardiac MRI to delineate morphological and functional features that are important for the choice of surgical approach and post-transplant complications [86].
Radiologic imaging in the surveillance of Fontan patients
What is the role of imaging in the surveillance of this patient group? No or very few evidence-based studies exist because of the still quite short observational period, and the proposed published guidelines until now were mainly based on experience in the adult age group. When a pediatric cardiologist follows a Fontan patient, his or her personal knowledge of how the other organs are affected will guide the surveillance by other clinical specialties. When these children reach early adolescence, their transition and follow-up from pediatric to adult care regarding both cardiology and radiology needs to be assured until successful commitment [9].
A statement from the American Heart Association from 2019 acknowledged that there is insufficient evidence base for developing clear recommendations but that cardiac and end-organ surveillance in children and adults is warranted and clinically important [5]. Furthermore, the statement said that monitoring should be performed by multidisciplinary Fontan/single-ventricle care clinics with health care personnel familiar with and experienced with Fontan circulation and complications [5]. It is expected that a surveillance protocol — the frequency and type of tests, including imaging — will, with the increased knowledge and experience from multicenter studies, be transformed in the future. Cardiac and end-organ imaging has an important part as a supplement to clinical assessment and other tests and should be carried out at defined intervals as proposed [5] and as discussed in this section.
Cardiovascular imaging assessment is already common at many institutions and should be performed in all age groups at set intervals. Cardiac MR with anatomical and functional investigation should be performed every 2–3 years and CT angiography when clinically indicated [47]. Cardiac catheterization is recommended once every 10 years or when clinically indicated [28].
End-organ status assessment is a newer concept where imaging and frequency should be tailored to patient age — every 3–4 years for children ages <12 years and every 1–3 years for adolescents ages 12–18 years. Findings at any test might change the interval for follow-up or initiate other investigations. The general imaging strategy should be as follows:
Lymphatic and endocrine system: MR lymphography with T2-weighted MR imaging as a new technique is recommended as likely to be of value as a part of a cardiac MR examination. Bone-age estimation and bone-mineral-density assessment are also recommended.
Brain and neurocognitive function: In addition to neurodevelopmental/cognitive testing, a brain MR examination can provide important information.
Lungs: Chest radiography is recommended.
Liver: Abdominal/liver US is recommended, including elastography if possible. MRI including liver biopsy might be considered. In the adolescent, this becomes even more important, especially monitoring liver disease development, because advanced-stage cirrhosis or even hepatocellular carcinoma might preclude transplantation. Annual US imaging with elastography has been proposed for adolescents ages 15–16 years, with more frequent controls if radiologic signs of fibrosis and nodules are found [52]. Some centers advocate annual liver MR from adolescence on, later combined with US elastography when routine biopsy is proposed [6, 7, 52].
However, the optimal management strategy for the pediatric population remains to be established [54].
Conclusion
Although the Fontan procedure has extended patients’ lifespan, an important risk of morbidity and mortality remains. Children receiving surgical treatment with a Fontan procedure at the time of birth require lifelong follow-up with medical care, implicating an important financial and societal impact. Still, much is unknown of how the Fontan palliation affects patients differently. End-organ effects are increasingly recognized, where mainly the cardiac, lymphatic and liver changes require monitoring with radiologic techniques to ensure the optimal timing for treatment and eventually cardiac transplantation. Increasing knowledge in pediatric radiology is urgently needed regarding this growing patient group and the pathology in end organs in addition to the cardiac changes.
Electronic supplementary material
Acknowledgments
Open Access funding provided by University of Oslo (incl Oslo University Hospital). I especially would like to thank Michael Bjaanes for his contribution in creating the figures and animations to illustrate the Fontan circulation.
Compliance with ethical standards
Conflicts of interest
None
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Change history
8/20/2020
In the original version of this paper there was an inadvertent misnumbering of references.
References
- 1.Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26:240–248. doi: 10.1136/thx.26.3.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Diab SG, Dohlen G, Seem E, Moller T (2019) [Fontan circulation with univentricular heart disease]. Tidsskr Nor Laegeforen 11:139 [DOI] [PubMed]
- 3.Rychik J. Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Cardiac Surg Annu. 2010;13:96–100. doi: 10.1053/j.pcsu.2010.02.006. [DOI] [PubMed] [Google Scholar]
- 4.Mori M, Aguirre AJ, Elder RW, et al. Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol. 2014;35:569–579. doi: 10.1007/s00246-014-0881-y. [DOI] [PubMed] [Google Scholar]
- 5.Rychik J, Atz AM, Celermajer DS et al (2019) Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 10.1161/CIR.0000000000000696 [DOI] [PubMed]
- 6.Daniels CJ, Bradley EA, Landzberg MJ, et al. Fontan-associated liver disease: proceedings from the American College of Cardiology stakeholders meeting, October 1 to 2, 2015, Washington DC. J Am Coll Cardiol. 2017;70:3173–3194. doi: 10.1016/j.jacc.2017.10.045. [DOI] [PubMed] [Google Scholar]
- 7.Munsterman ID, Duijnhouwer AL, Kendall TJ, et al. The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort. Eur Heart J. 2019;40:1057–1068. doi: 10.1093/eurheartj/ehy620. [DOI] [PubMed] [Google Scholar]
- 8.Tellez L, Rodriguez de Santiago E, Albillos A. Fontan-associated liver disease. Rev Esp Cardiol (Engl Ed) 2018;71:192–202. doi: 10.1016/j.rec.2017.10.052. [DOI] [PubMed] [Google Scholar]
- 9.Zentner D, Celermajer DS, Gentles T, et al. Management of people with a Fontan circulation: a Cardiac Society of Australia and New Zealand position statement. Heart Lung Circ. 2020;29:5–39. doi: 10.1016/j.hlc.2019.09.010. [DOI] [PubMed] [Google Scholar]
- 10.Schilling C, Dalziel K, Nunn R, et al. The Fontan epidemic: population projections from the Australia and New Zealand Fontan registry. Int J Cardiol. 2016;219:14–19. doi: 10.1016/j.ijcard.2016.05.035. [DOI] [PubMed] [Google Scholar]
- 11.Downing TE, Allen KY, Glatz AC, et al. Long-term survival after the Fontan operation: twenty years of experience at a single center. J Thorac Cardiovasc Surg. 2017;154:243–253. doi: 10.1016/j.jtcvs.2017.01.056. [DOI] [PubMed] [Google Scholar]
- 12.Khairy P, Fernandes SM, Mayer JE, Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85–92. doi: 10.1161/CIRCULATIONAHA.107.738559. [DOI] [PubMed] [Google Scholar]
- 13.Kverneland LS, Kramer P, Ovroutski S. Five decades of the Fontan operation: a systematic review of international reports on outcomes after univentricular palliation. Congenit Heart Dis. 2018;13:181–193. doi: 10.1111/chd.12570. [DOI] [PubMed] [Google Scholar]
- 14.Erikssen G, Aboulhosn J, Lin J, et al. Survival in patients with univentricular hearts: the impact of right versus left ventricular morphology. Open Heart. 2018;5:e000902. doi: 10.1136/openhrt-2018-000902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Atz AM, Zak V, Mahony L, et al. Longitudinal outcomes of patients with single ventricle after the Fontan procedure. J Am Coll Cardiol. 2017;69:2735–2744. doi: 10.1016/j.jacc.2017.03.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bolin EH, Maskatia SA, Tate AL, Petit CJ. Older age at completion of Fontan procedure is associated with improved percentage of predicted maximum oxygen uptake. Tex Heart Inst J. 2015;42:333–340. doi: 10.14503/THIJ-14-4178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kreutzer G, Galindez E, Bono H, et al. An operation for the correction of tricuspid atresia. J Thorac Cardiovasc Surg. 1973;66:613–621. [PubMed] [Google Scholar]
- 18.de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg. 1988;96:682–695. [PubMed] [Google Scholar]
- 19.Lemler MS, Scott WA, Leonard SR, et al. Fenestration improves clinical outcome of the Fontan procedure: a prospective, randomized study. Circulation. 2002;105:207–212. doi: 10.1161/hc0202.102237. [DOI] [PubMed] [Google Scholar]
- 20.Muller J, Christov F, Schreiber C, et al. Exercise capacity, quality of life, and daily activity in the long-term follow-up of patients with univentricular heart and total cavopulmonary connection. Eur Heart J. 2009;30:2915–2920. doi: 10.1093/eurheartj/ehp305. [DOI] [PubMed] [Google Scholar]
- 21.Rychik J. The relentless effects of the Fontan paradox. Semin Thorac Cardiovasc Surg Pediatr Cardiac Surg Annu. 2016;19:37–43. doi: 10.1053/j.pcsu.2015.11.006. [DOI] [PubMed] [Google Scholar]
- 22.Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg. 2006;82:695–700. doi: 10.1016/j.athoracsur.2006.02.048. [DOI] [PubMed] [Google Scholar]
- 23.Egbe AC, Poterucha JT, Warnes CA, et al. Hepatocellular carcinoma after Fontan operation. Circulation. 2018;138:746–748. doi: 10.1161/CIRCULATIONAHA.117.032717. [DOI] [PubMed] [Google Scholar]
- 24.Gewillig MH, Lundstrom UR, Deanfield JE, et al. Impact of Fontan operation on left ventricular size and contractility in tricuspid atresia. Circulation. 1990;81:118–127. doi: 10.1161/01.cir.81.1.118. [DOI] [PubMed] [Google Scholar]
- 25.Goldberg CS, Lu M, Sleeper LA, et al. Factors associated with neurodevelopment for children with single ventricle lesions. J Pediatr. 2014;165:490–496. doi: 10.1016/j.jpeds.2014.05.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Book WM, Gerardin J, Saraf A, et al. Clinical phenotypes of Fontan failure: implications for management. Congen Heart Dis. 2016;11:296–308. doi: 10.1111/chd.12368. [DOI] [PubMed] [Google Scholar]
- 27.Miller JR, Simpson KE, Epstein DJ, et al. Improved survival after heart transplant for failed Fontan patients with preserved ventricular function. J Heart Lung Transplant. 2016;35:877–883. doi: 10.1016/j.healun.2016.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Meyer SL, Ridderbos FS, Wolff D, et al. Serial cardiovascular magnetic resonance feature tracking indicates early worsening of cardiac function in Fontan patients. Int J Cardiol. 2020;303:23–29. doi: 10.1016/j.ijcard.2019.12.041. [DOI] [PubMed] [Google Scholar]
- 29.Stamm C, Anderson RH, Ho SY. The morphologically tricuspid valve in hypoplastic left heart syndrome. Eur J Cardiothorac Surg. 1997;12:587–592. doi: 10.1016/s1010-7940(97)00184-x. [DOI] [PubMed] [Google Scholar]
- 30.Honjo O, Mertens L, Van Arsdell GS. Atrioventricular valve repair in patients with single-ventricle physiology: mechanisms, techniques of repair, and clinical outcomes. Semin Thorac Cardiovasc Surg Pediatr Cardiac Surg Annu. 2011;14:75–84. doi: 10.1053/j.pcsu.2011.02.001. [DOI] [PubMed] [Google Scholar]
- 31.Kotani Y, Honjo O, Shani K, et al. Is indexed preoperative superior vena cava blood flow a risk factor in patients undergoing bidirectional cavopulmonary shunt? Ann Thorac Surg. 2012;94:1578–1583. doi: 10.1016/j.athoracsur.2012.05.043. [DOI] [PubMed] [Google Scholar]
- 32.Diller GP, Giardini A, Dimopoulos K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;31:3073–3083. doi: 10.1093/eurheartj/ehq356. [DOI] [PubMed] [Google Scholar]
- 33.Ghadimi Mahani M, Agarwal PP, Rigsby CK, et al. CT for assessment of thrombosis and pulmonary embolism in multiple stages of single-ventricle palliation: challenges and suggested protocols. Radiographics. 2016;36:1273–1284. doi: 10.1148/rg.2016150233. [DOI] [PubMed] [Google Scholar]
- 34.Ghelani SJ, Harrild DM, Gauvreau K, et al. Echocardiography and magnetic resonance imaging based strain analysis of functional single ventricles: a study of intra- and inter-modality reproducibility. Int J Cardiovasc Imaging. 2016;32:1113–1120. doi: 10.1007/s10554-016-0882-4. [DOI] [PubMed] [Google Scholar]
- 35.Nguyen KL, Han F, Zhou Z, et al. 4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart disease. J Cardiovasc Magn Reson. 2017;19:40. doi: 10.1186/s12968-017-0352-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Valsangiacomo Buechel ER, Grosse-Wortmann L, Fratz S, et al. Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the imaging working group of the AEPC and the cardiovascular magnetic resonance section of the EACVI. Eur Heart J Cardiovasc Imaging. 2015;16:281–297. doi: 10.1093/ehjci/jeu129. [DOI] [PubMed] [Google Scholar]
- 37.Warmerdam E, Krings GJ, Leiner T, Grotenhuis HB. Three-dimensional and four-dimensional flow assessment in congenital heart disease. Heart. 2020;106:421–426. doi: 10.1136/heartjnl-2019-315797. [DOI] [PubMed] [Google Scholar]
- 38.Kamphuis VP, Elbaz MSM, van den Boogaard PJ, et al. Stress increases intracardiac 4D flow cardiovascular magnetic resonance-derived energetics and vorticity and relates to VO2max in Fontan patients. J Cardiovasc Magn Reson. 2019;21:43. doi: 10.1186/s12968-019-0553-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Azarine A, Garcon P, Stansal A, et al. Four-dimensional flow MRI: principles and cardiovascular applications. Radiographics. 2019;39:632–648. doi: 10.1148/rg.2019180091. [DOI] [PubMed] [Google Scholar]
- 40.Kato A, Riesenkampff E, Yim D, et al. Pediatric Fontan patients are at risk for myocardial fibrotic remodeling and dysfunction. Int J Cardiol. 2017;240:172–177. doi: 10.1016/j.ijcard.2017.04.073. [DOI] [PubMed] [Google Scholar]
- 41.Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) J Cardiovasc Magn Reson. 2017;19:75. doi: 10.1186/s12968-017-0389-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Biko DM, DeWitt AG, Pinto EM, et al. MRI evaluation of lymphatic abnormalities in the neck and thorax after Fontan surgery: relationship with outcome. Radiology. 2019;291:774–780. doi: 10.1148/radiol.2019180877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Duerden L, Abdullah H, Lyen S et al (2019) Contrast circulation in adult Fontan patients using MR time resolved angiography: application for CT pulmonary angiography. J Cardiovasc Comput Tomogr. 10.1016/j.jcct.2019.12.035 [DOI] [PubMed]
- 44.Groves DW, Olivieri LJ, Shanbhag SM, et al. Feasibility of low radiation dose retrospectively-gated cardiac CT for functional analysis in adult congenital heart disease. Int J Cardiol. 2017;228:180–183. doi: 10.1016/j.ijcard.2016.11.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Cazzoli I, Gunturiz-Beltran C, Guarguagli S, et al. Catheter ablation for patients with end-stage complex congenital heart disease or cardiomyopathy considered for transplantation: trials and tribulations. Int J Cardiol. 2020;301:127–134. doi: 10.1016/j.ijcard.2019.09.021. [DOI] [PubMed] [Google Scholar]
- 46.Moore BM, Anderson R, Nisbet AM, et al. Ablation of atrial arrhythmias after the atriopulmonary Fontan procedure: mechanisms of arrhythmia and outcomes. JACC Clin Electrophysiol. 2018;4:1338–1346. doi: 10.1016/j.jacep.2018.08.012. [DOI] [PubMed] [Google Scholar]
- 47.Margossian R, Schwartz ML, Prakash A et al (2009) Comparison of echocardiographic and cardiac magnetic resonance imaging measurements of functional single ventricular volumes, mass, and ejection fraction (from the Pediatric Heart Network Fontan cross-sectional study). Am J Cardiol 104:419–428 [DOI] [PMC free article] [PubMed]
- 48.Bell A, Rawlins D, Bellsham-Revell H, et al. Assessment of right ventricular volumes in hypoplastic left heart syndrome by real-time three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2014;15:257–266. doi: 10.1093/ehjci/jet145. [DOI] [PubMed] [Google Scholar]
- 49.Fogel MA, Pawlowski TW, Whitehead KK, et al. Cardiac magnetic resonance and the need for routine cardiac catheterization in single ventricle patients prior to Fontan: a comparison of 3 groups: pre-Fontan CMR versus cath evaluation. J Am Coll Cardiol. 2012;60:1094–1102. doi: 10.1016/j.jacc.2012.06.021. [DOI] [PubMed] [Google Scholar]
- 50.Wells ML, Fenstad ER, Poterucha JT, et al. Imaging findings of congestive hepatopathy. Radiographics. 2016;36:1024–1037. doi: 10.1148/rg.2016150207. [DOI] [PubMed] [Google Scholar]
- 51.Agnoletti G, Ferraro G, Bordese R, et al. Fontan circulation causes early, severe liver damage. Should we offer patients a tailored strategy? Int J Cardiol. 2016;209:60–65. doi: 10.1016/j.ijcard.2016.02.041. [DOI] [PubMed] [Google Scholar]
- 52.Hilscher MB, Johnson JN, Cetta F, et al. Surveillance for liver complications after the Fontan procedure. Congen Heart Dis. 2017;12:124–132. doi: 10.1111/chd.12446. [DOI] [PubMed] [Google Scholar]
- 53.Yoo SJ, Prsa M, Schantz D, et al. MR assessment of abdominal circulation in Fontan physiology. Int J Cardiovasc Imaging. 2014;30:1065–1072. doi: 10.1007/s10554-014-0424-x. [DOI] [PubMed] [Google Scholar]
- 54.Nandwana SB, Olaiya B, Cox K, et al. Abdominal imaging surveillance in adult patients after Fontan procedure: risk of chronic liver disease and hepatocellular carcinoma. Curr Probl Diagn Radiol. 2017;47:19–22. doi: 10.1067/j.cpradiol.2017.04.002. [DOI] [PubMed] [Google Scholar]
- 55.Tellez L, Rodriguez de Santiago E, Minguez B, et al. Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: the VALDIG Fonliver prospective cohort. J Hepato. 2020;72:702–710. doi: 10.1016/j.jhep.2019.10.027. [DOI] [PubMed] [Google Scholar]
- 56.Patel ND, Sullivan PM, Sabati A et al (2020) Routine surveillance catheterization is useful in guiding management of stable Fontan patients. Pediatr Cardiol. 10.1007/s00246-020-02293-3 [DOI] [PubMed]
- 57.Horvat N, Rocha MS, Chagas AL, et al. Multimodality screening of hepatic nodules in patients with congenital heart disease after Fontan procedure: role of ultrasound, ARFI elastography, CT, and MRI. AJR Am J Roentgenol. 2018;211:1212–1220. doi: 10.2214/AJR.18.19762. [DOI] [PubMed] [Google Scholar]
- 58.Melero-Ferrer JL, Osa-Saez A, Buendia-Fuentes F, et al. Fontan circulation in adult patients: acoustic radiation force impulse elastography as a useful tool for liver assessment. World J Pediatr Congen Heart Surg. 2014;5:365–371. doi: 10.1177/2150135114530172. [DOI] [PubMed] [Google Scholar]
- 59.DiPaola FW, Schumacher KR, Goldberg CS, et al. Effect of Fontan operation on liver stiffness in children with single ventricle physiology. Eur Radiol. 2017;27:2434–2442. doi: 10.1007/s00330-016-4614-x. [DOI] [PubMed] [Google Scholar]
- 60.Rodriguez de Santiago E, Tellez L, Garrido-Lestache Rodriguez-Monte E, et al. Fontan protein-losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state. Liver Int. 2020;40:638–645. doi: 10.1111/liv.14375. [DOI] [PubMed] [Google Scholar]
- 61.Ntoulia A, Anupindi SA, Darge K, Back SJ. Applications of contrast-enhanced ultrasound in the pediatric abdomen. Abdom Radiol. 2018;43:948–959. doi: 10.1007/s00261-017-1315-0. [DOI] [PubMed] [Google Scholar]
- 62.Sidhu PS, Cantisani V, Deganello A, et al. Role of contrast-enhanced ultrasound (CEUS) in paediatric practice: an EFSUMB position statement. Ultraschall Med. 2017;38:33–43. doi: 10.1055/s-0042-110394. [DOI] [PubMed] [Google Scholar]
- 63.Cerny M, Chernyak V, Olivie D, et al. LI-RADS version 2018 ancillary features at MRI. Radiographics. 2018;38:1973–2001. doi: 10.1148/rg.2018180052. [DOI] [PubMed] [Google Scholar]
- 64.Bulut OP, Romero R, Mahle WT, et al. Magnetic resonance imaging identifies unsuspected liver abnormalities in patients after the Fontan procedure. J Pediatr. 2013;163:201–206. doi: 10.1016/j.jpeds.2012.12.071. [DOI] [PubMed] [Google Scholar]
- 65.Goldberg DJ, Surrey LF, Glatz AC et al (2017) Hepatic fibrosis is universal following Fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. J Am Heart Assoc 6 [DOI] [PMC free article] [PubMed]
- 66.Serai SD, Trout AT, Miethke A, et al. Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis. Pediatr Radiol. 2018;48:1256–1272. doi: 10.1007/s00247-018-4083-2. [DOI] [PubMed] [Google Scholar]
- 67.de Lange C, Reichert MJE, Pagano JJ, et al. Increased extracellular volume in the liver of pediatric Fontan patients. J Cardiovasc Magn Reson. 2019;21:39. doi: 10.1186/s12968-019-0545-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Poterucha JT, Johnson JN, Qureshi MY, et al. Magnetic resonance elastography: a novel technique for the detection of hepatic fibrosis and hepatocellular carcinoma after the Fontan operation. Mayo Clin Proc. 2015;90:882–894. doi: 10.1016/j.mayocp.2015.04.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Ohuchi H, Negishi J, Hayama Y, et al. Renal resistive index reflects Fontan pathophysiology and predicts mortality. Heart. 2017;103:1631–1637. doi: 10.1136/heartjnl-2016-310812. [DOI] [PubMed] [Google Scholar]
- 70.Rychik J, Dodds KM, Goldberg D, et al. Protein losing enteropathy after Fontan operation: glimpses of clarity through the lifting fog. World J Pediatr Congenit Heart Surg. 2020;11:92–96. doi: 10.1177/2150135119890555. [DOI] [PubMed] [Google Scholar]
- 71.Itkin M, Nadolski GJ. Modern techniques of lymphangiography and interventions: current status and future development. Cardiovasc Intervent Radiol. 2018;41:366–376. doi: 10.1007/s00270-017-1863-2. [DOI] [PubMed] [Google Scholar]
- 72.Dori Y. Novel lymphatic imaging techniques. Tech Vasc Interv Radiol. 2016;19:255–261. doi: 10.1053/j.tvir.2016.10.002. [DOI] [PubMed] [Google Scholar]
- 73.Itkin MG, McCormack FX, Dori Y. Diagnosis and treatment of lymphatic plastic bronchitis in adults using advanced lymphatic imaging and percutaneous embolization. Ann Am Thorac Soc. 2016;13:1689–1696. doi: 10.1513/AnnalsATS.201604-292OC. [DOI] [PubMed] [Google Scholar]
- 74.Diab SG, Godang K, Muller LO, et al. Progressive loss of bone mass in children with Fontan circulation. Congenit Heart Dis. 2019;14:996–1004. doi: 10.1111/chd.12848. [DOI] [PubMed] [Google Scholar]
- 75.Di Iorgi N, Maruca K, Patti G, Mora S. Update on bone density measurements and their interpretation in children and adolescents. Best Pract Res Clin Endocrinol Metab. 2018;32:477–498. doi: 10.1016/j.beem.2018.06.002. [DOI] [PubMed] [Google Scholar]
- 76.Sun L, Macgowan CK, Sled JG, et al. Reduced fetal cerebral oxygen consumption is associated with smaller brain size in fetuses with congenital heart disease. Circulation. 2015;131:1313–1323. doi: 10.1161/CIRCULATIONAHA.114.013051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Licht DJ, Shera DM, Clancy RR, et al. Brain maturation is delayed in infants with complex congenital heart defects. J Thorac Cardiovasc Surg. 2009;137:529–536. doi: 10.1016/j.jtcvs.2008.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Licht DJ, Wang J, Silvestre DW, et al. Preoperative cerebral blood flow is diminished in neonates with severe congenital heart defects. J Thorac Cardiovasc Surg. 2004;128:841–849. doi: 10.1016/j.jtcvs.2004.07.022. [DOI] [PubMed] [Google Scholar]
- 79.Claessens NHP, Breur J, Groenendaal F, et al. Brain microstructural development in neonates with critical congenital heart disease: an atlas-based diffusion tensor imaging study. Neuroimage Clin. 2019;21:101672. doi: 10.1016/j.nicl.2019.101672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Fogel MA, Li C, Elci OU, et al. Neurological injury and cerebral blood flow in single ventricles throughout staged surgical reconstruction. Circulation. 2017;135:671–682. doi: 10.1161/CIRCULATIONAHA.116.021724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Bellinger DC, Watson CG, Rivkin MJ, et al. Neuropsychological status and structural brain imaging in adolescents with single ventricle who underwent the Fontan procedure. J Am Heart Assoc. 2015;4:12. doi: 10.1161/JAHA.115.002302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Watson CG, Stopp C, Wypij D, et al. Reduced cortical volume and thickness and their relationship to medical and operative features in post-Fontan children and adolescents. Pediatr Res. 2017;81:881–890. doi: 10.1038/pr.2017.30. [DOI] [PubMed] [Google Scholar]
- 83.Greenway SC, Crossland DS, Hudson M, et al. Fontan-associated liver disease: implications for heart transplantation. J Heart Lung Transplant. 2016;35:26–33. doi: 10.1016/j.healun.2015.10.015. [DOI] [PubMed] [Google Scholar]
- 84.Rossano JW, Dipchand AI, Edwards LB, et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth pediatric heart transplantation report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1185–1195. doi: 10.1016/j.healun.2016.08.018. [DOI] [PubMed] [Google Scholar]
- 85.Tabarsi N, Guan M, Simmonds J, et al. Meta-analysis of the effectiveness of heart transplantation in patients with a failing Fontan. Am J Cardiol. 2017;119:1269–1274. doi: 10.1016/j.amjcard.2017.01.001. [DOI] [PubMed] [Google Scholar]
- 86.Chang PT, Frost J, Stanescu AL, et al. Pediatric thoracic organ transplantation: current indications, techniques, and imaging findings. Radiol Clin N Am. 2016;54:321–338. doi: 10.1016/j.rcl.2015.09.005. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.